ML130 (Nodinitib-1) is primarily investigated for its potential in cancer therapy due to its ability to inhibit NOD1 (nucleotide-binding oligomerization domain-containing protein 1), a key player in inflammatory signaling pathways that can influence tumor progression. By modulating NOD1 activity, ML130 shows promise in reducing inflammation-driven tumor growth and enhancing the efficacy of other anticancer agents. It has been used in preclinical studies to explore the role of innate immune pathways in cancer development, particularly in gastrointestinal and immune-related cancers. Additionally, ML130 serves as a research tool to dissect NOD1-dependent signaling mechanisms, supporting the development of targeted therapies for chronic inflammatory diseases and oncology.